BERKELEY HEIGHTS, N.J. — August 5, 2026 — Leads & Copy — Tonix Pharmaceuticals Holding Corp. announced that its management team will participate in two upcoming investor conferences in August and September 2026. President and Chief Executive Officer Seth Lederman, M.D., will present at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, Massachusetts. He will participate in a fireside chat from 1:30-1:55 p.m. ET.
Dr. Lederman will also participate in 1×1 meetings at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, in New York, New York.
A live webcast and replay of the Canaccord Genuity conference will be available under the News & Events tab in the Investors section of the Tonix website.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system disorders, infectious diseases, immunology conditions, and rare diseases with high unmet medical need. The company’s flagship product, TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first treatment for fibromyalgia in over 15 years. Tonix’s CNS commercial infrastructure supports its marketed acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg).
The company is also exploring the potential of TONMYA in Phase 2 clinical studies for major depressive disorder and acute stress disorder/acute stress reaction. Tonix’s pipeline includes infectious disease programs such as TNX-4800 (anti-OspA mAb) for Lyme disease prevention and TNX-801 (horsepox, live virus vaccine) for mpox and smallpox prevention. In immunology, Tonix is developing TNX-1500 (anti-CD40L mAb) for kidney transplant rejection. Additionally, the rare disease portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome.
Source: Tonix Pharmaceuticals Holding Corp.
